Pevion's therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity, while epidemiological survey confirms excellent market potential
Ittigen/Bern, Switzerland (ots) - Pevion Biotech AG today announced latest results from the ongoing clinical study of its therapeutic Candida vaccine PEV7, showing high levels of specific antibodies and a 100% mucosal immune response rate. The announcement further included the results of the largest, international ...
plus